Psilocybin-assisted PEARL Therapy for Cancer

(PEARL RCT Trial)

This trial explores whether psilocybin, a compound found in certain mushrooms, can improve mental well-being in people with advanced cancer. Participants will receive either a high or low dose of psilocybin in a supportive therapy setting called PEARL Therapy, which addresses existential and relational concerns. After the main study, those who received the low dose may opt to try the high dose. This trial suits individuals living in Ontario with stage IV solid tumor cancers or similar conditions, who have mild depression and are interested in therapy sessions. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.

Research has shown that psilocybin-assisted therapy is generally safe and well-tolerated. In earlier studies, cancer patients who received this treatment experienced fewer symptoms. These studies focused heavily on safety, and most participants did not report serious side effects. Common side effects included temporary feelings of anxiety or nausea, which were mild and short-lived.

Researchers are excited about psilocybin-assisted PEARL therapy for cancer patients because it represents a novel approach to addressing the psychological challenges of living with cancer. Unlike traditional treatments, which often focus on medications like antidepressants or talk therapy, this method combines the psychedelic compound psilocybin with Existential, Attachment, and Relational (PEARL) therapy. Psilocybin's unique mechanism works by potentially altering perception and cognition, which can help patients explore and process deep emotional and existential issues more effectively. This innovative approach could offer faster and more profound relief from anxiety and depression related to cancer, which is why it's generating significant interest in the medical community.

Research has shown that psilocybin-assisted PEARL therapy may help reduce distress in cancer patients. In this trial, participants will receive either a high dose or a low dose of psilocybin during PEARL therapy. Earlier studies found that patients who received psilocybin therapy experienced fewer symptoms of depression and felt less distress about the end of life. A small study also indicated that psilocybin-assisted group therapy could be safe and possibly beneficial for cancer patients. These findings suggest that using psilocybin with PEARL therapy might improve emotional well-being for those dealing with cancer.¹²³⁴⁵